Pomalidomide-PEG2-OH

Background Introduction

Pomalidomide-PEG2-OH is a cutting-edge E3 ligase ligand-linker conjugate designed to facilitate the development of PROTACs (Proteolysis Targeting Chimeras). This compound integrates pomalidomide, a well-characterized cereblon (CRBN) E3 ligase ligand, with a PEG2 (polyethylene glycol) linker terminated with a hydroxyl (-OH) group, providing versatile functionality for downstream chemical conjugation. As PROTACs continue to revolutionize targeted protein degradation, linker-payload conjugates like Pomalidomide-PEG2-OH are essential building blocks in the creation of next-generation therapeutics.

Mechanism

Pomalidomide-PEG2-OH operates as an E3 ligase-recruiting module in bifunctional molecules such as PROTACs. Pomalidomide selectively binds to the CRBN substrate receptor within the CUL4 E3 ubiquitin ligase complex. The PEG2 linker provides optimal spatial flexibility, allowing the terminal -OH group to be further coupled to a ligand that binds the target protein of interest (POI). Once a PROTAC is assembled using this conjugate, it enables the simultaneous recruitment of the E3 ligase and the POI, facilitating ubiquitination and subsequent proteasomal degradation of the target.

Applications

Pomalidomide-PEG2-OH finds widespread use in the design and synthesis of PROTAC molecules for targeted protein degradation. Researchers use this conjugate to create custom PROTACs against disease-relevant targets in oncology, neurology, and beyond. Its structure ensures reliable CRBN engagement while providing a functional handle for linking novel target ligands. The product streamlines the drug discovery process by simplifying PROTAC construction, supporting SAR (Structure-Activity Relationship) studies, and enabling rapid prototyping of degrader compounds in biological assays.

• Hydrophilic PEG2 linker improves solubility and pharmacokinetic properties in PROTAC development.
• Pomalidomide-based E3 ligase ligand ensures high affinity CRBN recruitment for effective target protein degradation.

Pomalidomide-PEG2-OH is a versatile E3 Ligase Ligand-Linker Conjugate used in the development of PROTACs, facilitating targeted protein degradation by connecting an E3 ligase ligand with a target protein ligand. The following provides a detailed description of this molecule.

Linker: The linker in Pomalidomide-PEG2-OH is a polyethylene glycol (PEG) chain with two ethylene glycol units, offering moderate flexibility. Its non-cleavable nature ensures stability, maintaining the integrity of the conjugate throughout the degradation process.

Ligand: The ligand component is derived from pomalidomide, a thalidomide analog known for its high affinity to the cereblon E3 ubiquitin ligase. Its structural characteristics enhance the recruitment of the ubiquitin-proteasome system, promoting effective protein degradation.

Reactive Site: The hydroxyl group at the terminal end of the PEG2 linker serves as the reactive site, enabling conjugation with target protein ligands. Recommended reaction types include esterification or carbamate formation, facilitating robust and stable linkages.

Recommended Target Protein Ligand: The recommended warhead for this molecule is a small-molecule inhibitor or modulator with a reactive functional group such as an amine or carboxylic acid. This compatibility ensures efficient conjugation, allowing researchers to design PROTACs that selectively degrade proteins of interest, expanding the scope of chemical biology and therapeutic research.